Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 for Treatment of Depression in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients, age greater than or equal to 21 years~* Diagnosis of Major Depressive Disorder determined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria with a Hamilton Depression Rating Scale Score greater than or equal to 18\*~* New York Heart Association Class greater than or equal to II~  * For patients with with left ventricular ejection fraction greater than 40 %, abnormal brain natriuretic peptide and/or previous hospitalization due to heart failure is also required~ * For inpatients, the Hamilton Depression Rating Scale scores need to be remain at 18 or above for two weeks following the discharge~Exclusion Criteria:~* Significant cognitive impairment, indicated as a Mini-Mental State Examination (MMSE) total score of 23 or lower~* History of alcohol or other drug dependence within the past 90 days~* Severe physical disability (visual, sensory, or motor) that may interfere with psychiatric assessment~* History or presence of psychoses, bipolar disorder, and/or severe personality disorders~* Life-threatening comorbidity with the likelihood of 50% mortality in one year~* Active suicidal ideations~* Current use of antipsychotic medications or psychotropic medications except Selective Serotonin Reuptake Inhibitors (SSRIs) and /or benzodiazepine~* Female patients who have a positive pregnancy test or are lactating. If female patients are of childbearing potential, they must use an effective and accepted means of contraception, such as oral contraceptives or a double-barrier method (condom and diaphragm) to protect against pregnancy~* Documented history of hypersensitivity or intolerance to omega 3 products; or use of omega 3 supplement for greater than or equal to 3 months at an equivalent or greater dose of the proposed study~* Treatment with electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within 90 days\*~* Uncorrected hypothyroidism or hyperthyroidism~* Treatment with any investigational agent within 1 month before randomization~* Acute coronary syndrome, i.e., Myocardial Infarction (MI) or unstable angina, revascularization procedure within the preceding month, or planned cardiac surgery within 3 months postrandomization~  * The exclusion of patients who received ECT or TMS within 90 days is adopted from other depression-intervention trials and meant to eliminate confounders. It is believed that the effects of ECT on mood and cognition may last for a couple of months, and duration of TMS effects is poorly known and may be similar to the ECT intervention.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2:1 EPA/DHA (Type: ACTIVE_COMPARATOR): 400/200 EPA/DHA fish oil 2 grams
- High EPA (Type: ACTIVE_COMPARATOR): Almost pure EPA 2 grams
- Placebo (Type: PLACEBO_COMPARATOR): Matched placebo corn oil capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).